SLC27A4

Summary

SLC27A4 (solute carrier family 27 member 4, HGNC:10998) is a protein-coding gene on chromosome 9q34.11, encoding Long-chain fatty acid transport protein 4 (Q6P1M0). Mediates the levels of long-chain fatty acids (LCFA) in the cell by facilitating their transport across cell membranes.

This gene encodes a member of a family of fatty acid transport proteins, which are involved in translocation of long-chain fatty acids cross the plasma membrane. This protein is expressed at high levels on the apical side of mature enterocytes in the small intestine, and appears to be the principal fatty acid transporter in enterocytes. Clinical studies suggest this gene as a candidate gene for the insulin resistance syndrome. Mutations in this gene have been associated with ichthyosis prematurity syndrome.

Source: NCBI Gene 10999 — RefSeq curated summary.

At a glance

• Gene–disease (curated): ichthyosis prematurity syndrome (Definitive, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 553 total — 28 pathogenic, 21 likely-pathogenic
• Phenotypes (HPO): 20
• Druggable target: yes
• MANE Select transcript: NM_005094

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10998
Approved symbol	SLC27A4
Name	solute carrier family 27 member 4
Location	9q34.11
Locus type	gene with protein product
Status	Approved
Aliases	FATP4, ACSVL4, FATP-4
Ensembl gene	ENSG00000167114
Ensembl biotype	protein_coding
OMIM	604194
Entrez	10999

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 20 protein_coding

ENST00000300456, ENST00000372870, ENST00000875273, ENST00000875274, ENST00000875275, ENST00000875276, ENST00000875277, ENST00000875278, ENST00000875279, ENST00000875280, ENST00000875281, ENST00000936236, ENST00000936237, ENST00000936238, ENST00000936239, ENST00000963238, ENST00000963239, ENST00000963240, ENST00000963241, ENST00000963242

RefSeq mRNA: 1 — MANE Select: NM_005094 NM_005094

CCDS: CCDS6899

Canonical transcript exons

ENST00000300456 — 13 exons

Exon	Start	End
ENSE00001109910	128355053	128355190
ENSE00001109931	128353415	128353541
ENSE00001109932	128355650	128355796
ENSE00001145261	128352638	128352747
ENSE00001145268	128350484	128350575
ENSE00001145277	128350312	128350381
ENSE00001145282	128348545	128348703
ENSE00001145289	128345155	128345549
ENSE00001379016	128353025	128353234
ENSE00001634746	128355398	128355562
ENSE00001710189	128343127	128343293
ENSE00001905619	128360334	128361470
ENSE00001921123	128340527	128340838

Expression profiles

Bgee: expression breadth ubiquitous, 219 present calls, max score 96.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.4281 / max 140.8232, expressed in 1766 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
98750	9.1522	1738
98752	3.9590	1327
98751	0.3169	132

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	96.48	gold quality
lower esophagus mucosa	UBERON:0035834	95.50	gold quality
jejunal mucosa	UBERON:0000399	95.00	gold quality
duodenum	UBERON:0002114	94.12	gold quality
upper arm skin	UBERON:0004263	94.03	silver quality
ileal mucosa	UBERON:0000331	93.03	gold quality
esophagus mucosa	UBERON:0002469	92.72	gold quality
prefrontal cortex	UBERON:0000451	91.43	gold quality
right frontal lobe	UBERON:0002810	90.71	gold quality
skin of leg	UBERON:0001511	90.23	gold quality
Brodmann (1909) area 9	UBERON:0013540	90.03	gold quality
hypothalamus	UBERON:0001898	89.92	gold quality
skin of abdomen	UBERON:0001416	89.74	gold quality
frontal cortex	UBERON:0001870	89.46	gold quality
left ventricle myocardium	UBERON:0006566	89.43	gold quality
anterior cingulate cortex	UBERON:0009835	89.29	gold quality
zone of skin	UBERON:0000014	88.82	gold quality
apex of heart	UBERON:0002098	88.80	gold quality
neocortex	UBERON:0001950	88.79	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	88.76	gold quality
oral cavity	UBERON:0000167	88.69	gold quality
jejunum	UBERON:0002115	88.51	gold quality
cardiac muscle of right atrium	UBERON:0003379	88.48	gold quality
pharyngeal mucosa	UBERON:0000355	88.37	gold quality
esophagus	UBERON:0001043	88.18	gold quality
right lobe of liver	UBERON:0001114	88.15	gold quality
substantia nigra	UBERON:0002038	88.14	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	88.08	gold quality
adult mammalian kidney	UBERON:0000082	87.81	gold quality
small intestine	UBERON:0002108	87.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.60

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): PPARG

miRNA regulators (miRDB)

70 targeting SLC27A4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-548AU-3P	99.70	68.22	1373

Literature-anchored findings (GeneRIF, showing 25)

• findings propose fatty acid transport protein 4 as a candidate gene for the insulin resistance syndrome (PMID:14715877)
• intra-pair correlations revealed that FATP4 expression was significantly up-regulated in acquired obesity." (PMID:15168018)
• Data suggest that endogenous FATP4 does not function to translocate fatty acids across the plasma membrane, but functions more as a very long-chain acyl-CoA synthetase. (PMID:17901542)
• Mutations in FATP4 gene cause the ichthyosis prematurity syndrome. (PMID:19631310)
• Mutation in FATP4 in a patient with self-healing congenital verruciform hyperkeratosis.( (PMID:20815031)
• even though hypoxia regulates the expression of FATP2 and FATP4 in human trophoblasts, mouse Fatp2 and Fatp4 are not essential for intrauterine fetal growth. (PMID:22028793)
• FATP1 and FATP4 proteins perform different functional roles in handling long chain fatty acids in skeletal muscle (PMID:22235293)
• FATP4 plays crucial roles in the development and maturation of both sebaceous and meibomian glands, as well as in the formation and composition of sebum (PMID:23271751)
• FATP4, ichthyin and TGM1 interact in lipid processing essential for maintaining the epidermal barrier function (PMID:23290633)
• the clinical implications of defects in these transporters and relevant animal models, including the FATP4 animal models and ichthyosis prematurity syndrome, a congenital ichthyosis caused by FATP4 deficiency. [review] (PMID:24120574)
• the cell surface protein CD36/FAT directly facilitates fatty acid transport across the plasma membrane, whereas the intracellular acyl-CoA synthetases FATP4 and ACSL1 enhance fatty acid uptake indirectly by metabolic trapping (PMID:24503477)
• We describe two siblings with ichthyosis prematurity syndrome and report a recurrent homozygous mutation (c.1430T>A) that is predicted to lead to a p.Val477Asp substitution in fatty acid transport protein 4. (PMID:24889544)
• SLC27A4 gene mutation is responsible in the diagnosis of ichthyosis prematurity syndrome in a premature infant. (PMID:26341232)
• we resequenced the SLC27A3 and SLC27A4 genes using 267 autism spectrum disorders(ASD) patient and 1140 control samples and detected 47 and 30 variants for the SLC27A3 and SLC27A4, revealing that they are highly polymorphic with multiple rare variants. (PMID:26548558)
• The results have interesting implications that SLC27A4/ATG4B complex might be conducive to the occurrence of autophagy in human cancer cells, which is meaningful investigations toward the aim of developing autophagy-targeting drugs and have significant values in clinical application. (PMID:26662804)
• no association between placental expression and maternal body mass index (PMID:27016784)
• expand the mutational repertory of FATP4 with three undescribed pathogenic mutations in two families (PMID:27168232)
• Case Report: ichthyosis prematurity syndrome caused by novel homozygous mutation in SLC27A4. (PMID:29701233)
• high SLC27A4 is associated with tumor progression in breast cancer cells. (PMID:30388870)
• High FATP4 expression was associated with poor prognosis in clear cell renal cell carcinoma. (PMID:31089396)
• Impacts of deletion and ichthyosis prematurity syndrome-associated mutations in fatty acid transport protein 4 on the function of RPE65. (PMID:31595490)
• The positive feedback between ACSL4 expression and O-GlcNAcylation contributes to the growth and survival of hepatocellular carcinoma. (PMID:32357142)
• Physical Activity During Pregnancy Is Associated with Increased Placental FATP4 Protein Expression. (PMID:32519158)
• SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma. (PMID:36924851)
• PLIN5 interacts with FATP4 at membrane contact sites to promote lipid droplet-to-mitochondria fatty acid transport. (PMID:37290445)

Cross-species orthologs

27 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc27a4	ENSDARG00000017047
mus_musculus	Slc27a4	ENSMUSG00000059316
rattus_norvegicus	Slc27a4	ENSRNOG00000014369
drosophila_melanogaster	bgm	FBGN0027348
drosophila_melanogaster	pdgy	FBGN0027601
drosophila_melanogaster	CG8834	FBGN0033733
drosophila_melanogaster	CG17999	FBGN0034552
drosophila_melanogaster	CG9993	FBGN0034553
drosophila_melanogaster	Fatp3	FBGN0034999
drosophila_melanogaster	CG4563	FBGN0035006
drosophila_melanogaster	CG5568	FBGN0035641
drosophila_melanogaster	CG18586	FBGN0035642
drosophila_melanogaster	CG4830	FBGN0037996
drosophila_melanogaster	Acsx1L	FBGN0038730
drosophila_melanogaster	Acsx1R	FBGN0038731
drosophila_melanogaster	Acsx2	FBGN0038732
drosophila_melanogaster	Acsx3	FBGN0038733
drosophila_melanogaster	Acsx4	FBGN0038734
drosophila_melanogaster	Fatp2	FBGN0265187
drosophila_melanogaster	Fatp1	FBGN0267828
drosophila_melanogaster	hll	FBGN0286723
caenorhabditis_elegans		WBGENE00007082
caenorhabditis_elegans		WBGENE00008669
caenorhabditis_elegans		WBGENE00009218
caenorhabditis_elegans		WBGENE00011173
caenorhabditis_elegans		WBGENE00019920
caenorhabditis_elegans		WBGENE00022849

Paralogs (12): ACSL4 (ENSG00000068366), SLC27A5 (ENSG00000083807), ACSBG1 (ENSG00000103740), SLC27A6 (ENSG00000113396), ACSL3 (ENSG00000123983), SLC27A1 (ENSG00000130304), ACSBG2 (ENSG00000130377), SLC27A2 (ENSG00000140284), SLC27A3 (ENSG00000143554), ACSL1 (ENSG00000151726), ACSL6 (ENSG00000164398), ACSL5 (ENSG00000197142)

Protein

Protein identifiers

Long-chain fatty acid transport protein 4 — Q6P1M0 (reviewed: Q6P1M0)

Alternative names: Arachidonate–CoA ligase, Long-chain-fatty-acid–CoA ligase, Solute carrier family 27 member 4, Very long-chain acyl-CoA synthetase 4

All UniProt accessions (1): Q6P1M0

UniProt curated annotations — full annotation on UniProt →

Function. Mediates the levels of long-chain fatty acids (LCFA) in the cell by facilitating their transport across cell membranes. Appears to be the principal fatty acid transporter in small intestinal enterocytes. Also functions as an acyl-CoA ligase catalyzing the ATP-dependent formation of fatty acyl-CoA using LCFA and very-long-chain fatty acids (VLCFA) as substrates, which prevents fatty acid efflux from cells and might drive more fatty acid uptake. Plays a role in the formation of the epidermal barrier. Required for fat absorption in early embryogenesis. Probably involved in fatty acid transport across the blood barrier. Indirectly inhibits RPE65 via substrate competition and via production of VLCFA derivatives like lignoceroyl-CoA. Prevents light-induced degeneration of rods and cones.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Expressed at highest levels in brain, testis, colon and kidney. Expressed at medium levels in heart and liver, small intestine and stomach. Expressed at low levels in peripheral leukocytes, bone marrow, skeletal muscle and aorta. Expressed in adipose tissue. Expressed in brain gray matter.

Disease relevance. Ichthyosis prematurity syndrome (IPS) [MIM:608649] A keratinization disorder characterized by complications in the second trimester of pregnancy resulting from polyhydramnion, with premature birth of a child with thick caseous desquamating epidermis, respiratory complications and transient eosinophilia. After recovery during the first months of life, the symptoms are relatively benign and the patients suffer from a lifelong non-scaly ichthyosis with atopic manifestations. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. SLC27A4/FATP4-mediated fatty acid uptake is associated to paramaters related to insulin resistance, which is associated with disturbed fatty acid metabolism and homeostasis, such as obesity. SLC27A4/FATP4 expression is positively correlated with acquired obesity.

Similarity. Belongs to the ATP-dependent AMP-binding enzyme family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6P1M0-1	1	yes
Q6P1M0-2	2

RefSeq proteins (1): NP_005085* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000873	AMP-dep_synth/lig_dom	Domain
IPR020845	AMP-binding_CS	Conserved_site
IPR022272	Lipocalin_CS	Conserved_site
IPR025110	AMP-bd_C	Domain
IPR042099	ANL_N_sf	Homologous_superfamily
IPR045851	AMP-b_sf	Homologous_superfamily

Pfam: PF00501, PF13193

Enzyme classification (BRENDA):

• EC 6.2.1.3 — long-chain-fatty-acid-CoA ligase (BRENDA: 48 organisms, 205 substrates, 100 inhibitors, 159 Km, 11 kcat entries)

Substrate kinetics (BRENDA)

48 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.025–12.21	28
COA	0.0005–4.7	21
PALMITATE	0.0002–6	19
OLEATE	0.0014–3	9
ARACHIDONATE	0.0065–9.7	6
STEARATE	0.0002–0.12	6
DECANOATE	0.004–0.0083	4
LAURATE	0.0005–0.002	4
LINOLEATE	0.0022–0.041	4
MYRISTATE	0.0002–0.0024	4
OCTANOATE	0.0007–0.0408	4
LAURIC ACID	0.0017–0.0163	3
LINOLENATE	0.0016–0.0073	2
OCTADECANOATE	0.061–0.072	2
PALMITOLEATE	0.0015–0.002	2

Catalyzed reactions (Rhea), 11 shown:

• a long-chain fatty acid + ATP + CoA = a long-chain fatty acyl-CoA + AMP + diphosphate (RHEA:15421)
• (5Z,8Z,11Z,14Z)-eicosatetraenoate + ATP + CoA = (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate (RHEA:19713)
• hexadecanoate + ATP + CoA = hexadecanoyl-CoA + AMP + diphosphate (RHEA:30751)
• (9Z)-octadecenoate + ATP + CoA = (9Z)-octadecenoyl-CoA + AMP + diphosphate (RHEA:33607)
• tetracosanoate + ATP + CoA = tetracosanoyl-CoA + AMP + diphosphate (RHEA:33639)
• (9Z)-octadecenoate(out) = (9Z)-octadecenoate(in) (RHEA:33655)
• (E)-hexadec-2-enoate + ATP + CoA = (2E)-hexadecenoyl-CoA + AMP + diphosphate (RHEA:36139)
• a fatty acid(in) = a fatty acid(out) (RHEA:38879)
• hexadecanoate(out) = hexadecanoate(in) (RHEA:45256)
• (9Z,12Z)-octadecadienoate(out) = (9Z,12Z)-octadecadienoate(in) (RHEA:45264)
• a very long-chain fatty acid + ATP + CoA = a very long-chain fatty acyl-CoA + AMP + diphosphate (RHEA:54536)

UniProt features (14 total): sequence variant 6, transmembrane region 2, sequence conflict 2, splice variant 2, chain 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6P1M0-F1	90.72	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 243–254

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-5619108	Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS)
R-HSA-804914	Transport of fatty acids
R-HSA-1643685	Disease
R-HSA-382551	Transport of small molecules
R-HSA-425397	Transport of vitamins, nucleosides, and related molecules
R-HSA-425407	SLC-mediated transmembrane transport
R-HSA-5619102	SLC transporter disorders
R-HSA-5619115	Disorders of transmembrane transporters

MSigDB gene sets: 230 (showing top): GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_FATTY_ACID_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_TRANSPORT, GOBP_CIRCULATORY_SYSTEM_PROCESS, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, TGACCTY_ERR1_Q2, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_CELLULAR_RESPONSE_TO_INSULIN_STIMULUS, GOBP_ORGANIC_ACID_TRANSPORT, WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS

GO Biological Process (18): medium-chain fatty acid transport (GO:0001579), long-chain fatty acid metabolic process (GO:0001676), fatty acid metabolic process (GO:0006631), response to nutrient (GO:0007584), fatty acid transport (GO:0015908), long-chain fatty acid transport (GO:0015909), very long-chain fatty acid catabolic process (GO:0042760), positive regulation of apoptotic process (GO:0043065), skin development (GO:0043588), glucose import in response to insulin stimulus (GO:0044381), long-chain fatty acid import into cell (GO:0044539), negative regulation of insulin receptor signaling pathway (GO:0046627), establishment of localization in cell (GO:0051649), transport across blood-brain barrier (GO:0150104), lipid transport across blood-brain barrier (GO:1990379), very long-chain fatty acid metabolic process (GO:0000038), lipid metabolic process (GO:0006629), lipid transport (GO:0006869)

GO Molecular Function (10): nucleotide binding (GO:0000166), long-chain fatty acid-CoA ligase activity (GO:0004467), long-chain fatty acid transmembrane transporter activity (GO:0005324), fatty acid transmembrane transporter activity (GO:0015245), very long-chain fatty acid-CoA ligase activity (GO:0031957), arachidonate-CoA ligase activity (GO:0047676), palmitoyl-CoA ligase activity (GO:0090433), oleoyl-CoA ligase activity (GO:0090434), protein binding (GO:0005515), ligase activity (GO:0016874)

GO Cellular Component (6): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), microvillus (GO:0005902), membrane (GO:0016020), brush border membrane (GO:0031526)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
SLC transporter disorders	1
Transport of vitamins, nucleosides, and related molecules	1
SLC-mediated transmembrane transport	1
Transport of small molecules	1
Disorders of transmembrane transporters	1
Disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
fatty acid transport	3
long-chain fatty acid-CoA ligase activity	3
fatty acid metabolic process	2
lipid transport	2
long-chain fatty acid transport	2
fatty acid-CoA ligase activity	2
lipid metabolic process	1
monocarboxylic acid metabolic process	1
response to nutrient levels	1
response to chemical	1
monocarboxylic acid transport	1
very long-chain fatty acid metabolic process	1
fatty acid catabolic process	1
apoptotic process	1
regulation of apoptotic process	1
positive regulation of programmed cell death	1
animal organ development	1
cellular response to insulin stimulus	1
D-glucose import across plasma membrane	1
import into cell	1
lipid import into cell	1
insulin receptor signaling pathway	1
negative regulation of signal transduction	1
regulation of insulin receptor signaling pathway	1
negative regulation of cellular response to insulin stimulus	1
establishment of localization	1
cellular localization	1
vascular transport	1
transport across blood-brain barrier	1
primary metabolic process	1
transport	1
lipid localization	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
long-chain fatty acid metabolic process	1
fatty acid transmembrane transporter activity	1
monocarboxylic acid transmembrane transporter activity	1
lipid transmembrane transporter activity	1
binding	1
catalytic activity	1

Protein interactions and networks

STRING

1784 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC27A4	AASDH	Q4L235	843
SLC27A4	ACSL1	P33121	791
SLC27A4	CD36	P16671	742
SLC27A4	SCARB1	Q8WTV0	719
SLC27A4	SCARB2	Q14108	718
SLC27A4	PPARA	Q07869	701
SLC27A4	COASY	Q13057	695
SLC27A4	NIPAL4	Q0D2K0	681
SLC27A4	PNPLA1	Q8N8W4	663
SLC27A4	PPARG	P37231	651
SLC27A4	LIPE	Q05469	632
SLC27A4	GOT2	P00505	632
SLC27A4	PPARD	Q03181	605
SLC27A4	CAV1	Q03135	589
SLC27A4	CYP4F22	Q6NT55	580
SLC27A4	PLIN1	O60240	580

IntAct

96 interactions, top by confidence:

A	B	Type	Score
BECN1	ZWINT	psi-mi:“MI:0914”(association)	0.750
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
PCNA	POM121C	psi-mi:“MI:0914”(association)	0.550
PEX19	FAM20B	psi-mi:“MI:0914”(association)	0.530
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
CD63	LGALS8	psi-mi:“MI:0914”(association)	0.530
GPN3	POLR3A	psi-mi:“MI:0914”(association)	0.530
OGFOD3	CLGN	psi-mi:“MI:0914”(association)	0.530
ARMC6	SLC27A2	psi-mi:“MI:0914”(association)	0.530
PBXIP1	KCNN4	psi-mi:“MI:0914”(association)	0.530
PEX19	MYO1D	psi-mi:“MI:0914”(association)	0.530
pipB2	SCD	psi-mi:“MI:0914”(association)	0.460
vpu	SCAMP3	psi-mi:“MI:0914”(association)	0.460
SMUG1	SLC27A4	psi-mi:“MI:0915”(physical association)	0.400
SLC27A4	EPS8	psi-mi:“MI:0915”(physical association)	0.370
OTUB1		psi-mi:“MI:0914”(association)	0.350
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350
Tpx2	NFKBIE	psi-mi:“MI:0914”(association)	0.350
Dennd6a	IFT88	psi-mi:“MI:0914”(association)	0.350
Strn3	STK24	psi-mi:“MI:0914”(association)	0.350
Sod1	ZC3H18	psi-mi:“MI:0914”(association)	0.350
	ESYT2	psi-mi:“MI:0914”(association)	0.350
	PGRMC1	psi-mi:“MI:0914”(association)	0.350
	HAX1	psi-mi:“MI:0914”(association)	0.350

BioGRID (319): SLC27A4 (Affinity Capture-RNA), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-MS), SLC27A4 (Affinity Capture-RNA), SLC27A4 (Affinity Capture-MS)

ESM2 similar proteins: A2AI05, D3ZDK7, E1BNQ4, O55240, O70249, P21139, P24298, P25409, P50336, P51175, P56602, P97849, Q03426, Q1JPJ0, Q27979, Q2KJF7, Q3T0A0, Q3ZKN0, Q498R1, Q4JIJ2, Q5E9M9, Q5E9T8, Q5R7A2, Q5RK23, Q60714, Q60HD5, Q6AYG0, Q6NRG5, Q6P1M0, Q6P3E7, Q6PCB7, Q6PFP6, Q7TSA0, Q8BNV1, Q8BZG5, Q8C1A3, Q8CHP8, Q8IXI1, Q8JZN7, Q8QZR5

Diamond homologs: A0A0A2J5U8, A1U2S9, B2KWI3, C1AA44, J5JLF2, K0E2F3, O07610, O53521, O68040, P13129, P16929, P27095, P38135, P63521, P63522, P69451, P69452, P94547, P9WQ44, P9WQ45, Q07VK4, Q0AFF1, Q0K844, Q0P4F7, Q15YI8, Q17QJ1, Q26304, Q336M7, Q42524, Q42982, Q499N5, Q4R3Y4, Q4WR83, Q54P78, Q5RDY4, Q5SIW6, Q6BS00, Q6MNF1, Q6P1M0, Q72J95

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SLC27A4	“up-regulates quantity”	“Fatty acid”	relocalization

Disease & clinical

Clinical variants and AI predictions

ClinVar

553 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	28
Likely pathogenic	21
Uncertain significance	130
Likely benign	320
Benign	17

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1171020	NM_005094.4(SLC27A4):c.1208G>A (p.Cys403Tyr)	Pathogenic
1171021	NM_005094.4(SLC27A4):c.1529G>A (p.Arg510His)	Pathogenic
1171022	NM_005094.4(SLC27A4):c.1322dup (p.Gly442fs)	Pathogenic
1171023	NM_005094.4(SLC27A4):c.988-19A>G	Pathogenic
1686197	NM_005094.4(SLC27A4):c.1065del (p.Arg356fs)	Pathogenic
2014020	NM_005094.4(SLC27A4):c.878-1G>A	Pathogenic
225105	NM_005094.4(SLC27A4):c.1774G>A (p.Gly592Arg)	Pathogenic
2425294	NC_000009.11:g.(?131107414)(131112874_?)del	Pathogenic
2704558	NM_005094.4(SLC27A4):c.1461_1462del (p.Thr487_Gly488insTer)	Pathogenic
2704779	NM_005094.4(SLC27A4):c.1369del (p.Leu457fs)	Pathogenic
2735354	NM_005094.4(SLC27A4):c.1A>G (p.Met1Val)	Pathogenic
2753014	NM_005094.4(SLC27A4):c.1394del (p.Asn465fs)	Pathogenic
2766751	NM_005094.4(SLC27A4):c.1167C>A (p.Cys389Ter)	Pathogenic
2773196	NM_005094.4(SLC27A4):c.1060C>T (p.Gln354Ter)	Pathogenic
2795966	NM_005094.4(SLC27A4):c.28del (p.Val10fs)	Pathogenic
2796897	NM_005094.4(SLC27A4):c.1318C>T (p.Gln440Ter)	Pathogenic
2822452	NM_005094.4(SLC27A4):c.839del (p.Asp280fs)	Pathogenic
2866939	NM_005094.4(SLC27A4):c.863del (p.Leu288fs)	Pathogenic
2878187	NM_005094.4(SLC27A4):c.1711A>T (p.Lys571Ter)	Pathogenic
3245333	NC_000009.11:g.(?131115674)(131115840_?)del	Pathogenic
3245334	NC_000009.11:g.(?131105412)(131107848_?)del	Pathogenic
3245335	NC_000009.11:g.(?131108613)(131112753_?)del	Pathogenic
3254621	NM_005094.4(SLC27A4):c.871_877+19del	Pathogenic
3616805	NM_005094.4(SLC27A4):c.1104G>A (p.Trp368Ter)	Pathogenic
3657765	NM_005094.4(SLC27A4):c.916_919del (p.Met306fs)	Pathogenic
5744	NM_005094.4(SLC27A4):c.274G>A (p.Ala92Thr)	Pathogenic
5747	NM_005094.4(SLC27A4):c.988-2A>G	Pathogenic
872094	NM_005094.4(SLC27A4):c.1211_1215del (p.Gly404fs)	Pathogenic
1474709	NM_005094.4(SLC27A4):c.715+1G>T	Likely pathogenic
1696265	NM_005094.4(SLC27A4):c.-6-2A>G	Likely pathogenic

SpliceAI

1919 predictions. Top by Δscore:

Variant	Effect	Δscore
9:128340834:GCCGG:G	donor_gain	1.0000
9:128340836:CGGG:C	donor_loss	1.0000
9:128340837:GG:G	donor_gain	1.0000
9:128340838:GG:G	donor_gain	1.0000
9:128340838:GGT:G	donor_loss	1.0000
9:128340839:G:GG	donor_gain	1.0000
9:128343121:CCGCA:C	acceptor_loss	1.0000
9:128343123:GCAG:G	acceptor_loss	1.0000
9:128343124:CA:C	acceptor_loss	1.0000
9:128343125:A:AG	acceptor_gain	1.0000
9:128343125:AGGC:A	acceptor_loss	1.0000
9:128343126:G:GG	acceptor_gain	1.0000
9:128343126:GGCC:G	acceptor_gain	1.0000
9:128343126:GGCCA:G	acceptor_gain	1.0000
9:128343289:ATCTT:A	donor_gain	1.0000
9:128343290:TCTT:T	donor_gain	1.0000
9:128343292:TT:T	donor_gain	1.0000
9:128343294:G:GG	donor_gain	1.0000
9:128343295:T:A	donor_loss	1.0000
9:128343296:GAG:G	donor_loss	1.0000
9:128345149:A:AG	acceptor_gain	1.0000
9:128345150:C:G	acceptor_gain	1.0000
9:128345151:ACAGT:A	acceptor_gain	1.0000
9:128345152:C:G	acceptor_gain	1.0000
9:128345153:A:AG	acceptor_gain	1.0000
9:128345153:AGT:A	acceptor_gain	1.0000
9:128345154:G:GT	acceptor_gain	1.0000
9:128345154:GT:G	acceptor_gain	1.0000
9:128345154:GTG:G	acceptor_gain	1.0000
9:128345154:GTGGC:G	acceptor_gain	1.0000

AlphaMissense

4165 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:128350339:G:A	G248D	1.000
9:128355400:G:C	D489H	1.000
9:128355401:A:G	D489G	1.000
9:128355401:A:T	D489V	1.000
9:128355445:C:A	R504S	1.000
9:128355446:G:C	R504P	1.000
9:128350338:G:C	G248R	0.999
9:128350338:G:T	G248C	0.999
9:128350339:G:T	G248V	0.999
9:128350363:C:A	A256D	0.999
9:128350381:G:T	R262M	0.999
9:128350566:C:G	H290D	0.999
9:128350568:C:A	H290Q	0.999
9:128350568:C:G	H290Q	0.999
9:128352638:G:A	G293E	0.999
9:128352700:T:C	F314L	0.999
9:128352702:C:A	F314L	0.999
9:128352702:C:G	F314L	0.999
9:128352718:T:A	W320R	0.999
9:128352718:T:C	W320R	0.999
9:128352729:T:G	C323W	0.999
9:128352744:C:G	C328W	0.999
9:128353059:T:C	L341P	0.999
9:128353122:G:A	G362D	0.999
9:128353191:G:A	G385E	0.999
9:128353197:C:T	T387I	0.999
9:128353199:G:A	E388K	0.999
9:128353200:A:T	E388V	0.999
9:128353207:C:A	N390K	0.999
9:128353207:C:G	N390K	0.999

dbSNP variants (sampled 300 via entrez): RS1000465116 (9:128356327 G>A), RS1000798464 (9:128357819 C>A,T), RS1000822737 (9:128345384 A>G), RS1001018277 (9:128345781 C>T), RS1001282272 (9:128345694 A>G), RS1001312303 (9:128351961 C>T), RS1001372129 (9:128361021 A>T), RS1001394841 (9:128340172 C>T), RS1001424550 (9:128360756 A>C,G), RS1001741353 (9:128340059 T>C), RS1001874724 (9:128344407 T>C,G), RS1001875013 (9:128339313 G>A), RS1002197318 (9:128357129 G>A,T), RS1002218318 (9:128356628 AC>A), RS1002223741 (9:128344177 T>G)

Disease associations

OMIM: gene MIM:604194 | disease phenotypes: MIM:608649, MIM:242300

GenCC curated gene-disease

Disease	Classification	Inheritance
ichthyosis prematurity syndrome	Definitive	Autosomal recessive

Mondo (3): ichthyosis prematurity syndrome (MONDO:0012089), lamellar ichthyosis (MONDO:0017778), autosomal recessive congenital ichthyosis (MONDO:0017265)

Orphanet (3): Ichthyosis-prematurity syndrome (Orphanet:88621), Lamellar ichthyosis (Orphanet:313), Autosomal recessive congenital ichthyosis (Orphanet:281097)

HPO phenotypes

20 total (20 of 20 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000953	Hyperpigmentation of the skin
HP:0000989	Pruritus
HP:0001019	Erythroderma
HP:0001561	Polyhydramnios
HP:0001622	Premature birth
HP:0001880	Increased total eosinophil count
HP:0002099	Asthma
HP:0002293	Alopecia of scalp
HP:0002643	Neonatal respiratory distress
HP:0003193	Allergic rhinitis
HP:0007502	Follicular hyperkeratosis
HP:0007503	Generalized ichthyosis
HP:0007549	Desquamation of skin soon after birth
HP:0008064	Ichthyosis
HP:0011971	Dermatographic urticaria
HP:0012768	Neonatal asphyxia
HP:0025092	Epidermal acanthosis
HP:0025724	Caseous vernix-like desquamation
HP:0500093	Food allergy

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005951_65	Body mass index	5.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C536271	Ichthyosis prematurity syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4327 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC27 family of fatty acid transporters

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
compound 1l [PMID: 16644217]	Inhibition	7.05	pIC50

ChEMBL bioactivities

28 potent at pChembl≥5 of 32 total, top 28 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.05	IC50	90	nM	CHEMBL209855
6.82	IC50	150	nM	CHEMBL211612
6.75	IC50	180	nM	CHEMBL426323
6.70	IC50	200	nM	CHEMBL211941
6.60	IC50	250	nM	CHEMBL211864
6.58	IC50	260	nM	CHEMBL211117
6.30	IC50	500	nM	CHEMBL437303
6.22	IC50	600	nM	CHEMBL212149
6.19	IC50	640	nM	CHEMBL378290
6.19	IC50	650	nM	CHEMBL211772
6.16	IC50	700	nM	CHEMBL212012
6.00	IC50	1000	nM	CHEMBL211656
6.00	IC50	1000	nM	CHEMBL211182
6.00	IC50	1000	nM	CHEMBL208649
5.96	IC50	1100	nM	CHEMBL212361
5.92	IC50	1200	nM	CHEMBL436931
5.92	IC50	1200	nM	CHEMBL211547
5.92	IC50	1200	nM	CHEMBL209702
5.85	IC50	1400	nM	CHEMBL209249
5.82	IC50	1500	nM	CHEMBL211116
5.70	IC50	2000	nM	CHEMBL380109
5.62	IC50	2400	nM	CHEMBL380014
5.47	IC50	3400	nM	CHEMBL377744
5.35	IC50	4500	nM	CHEMBL209337
5.30	IC50	5000	nM	CHEMBL211057
5.10	IC50	8000	nM	CHEMBL210290
5.10	IC50	8000	nM	CHEMBL439325
5.02	IC50	9500	nM	CHEMBL377528

PubChem BioAssay actives

28 with measured affinity, of 53 total; 27 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(E)-hept-2-enyl] 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.0900	uM
(4-ethylcyclohexyl) 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.1500	uM
cyclohex-2-en-1-yl 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.1800	uM
cyclopentyl (4S)-6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.2000	uM
cyclopentyl 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.2500	uM
[(E)-hex-2-enyl] 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.2600	uM
cyclohexyl 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.5000	uM
cyclopentyl (4S)-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.6000	uM
[(E)-pent-2-enyl] 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.6400	uM
[(E)-but-2-enyl] 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.6500	uM
[(Z)-pent-2-enyl] 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	0.7000	uM
cyclopentyl 4-(4-bromophenyl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	1.0000	uM
cyclopentyl 4-(4-chlorophenyl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	1.0000	uM
cyclopentyl 6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	1.0000	uM
cyclopentyl 6-methyl-2-oxo-4-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	1.1000	uM
2-ethylsulfanylethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	1.2000	uM
cycloheptyl 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	1.2000	uM
cyclobutyl 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	1.2000	uM
cyclopentyl 4-(4-cyanophenyl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	1.4000	uM
prop-2-enyl 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	1.5000	uM
pentyl 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	2.0000	uM
cyclopentyl 6-methyl-4-(4-nitrophenyl)-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	3.4000	uM
cyclopentyl 6-methyl-4-(4-methylphenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	4.5000	uM
cyclopentyl 4-(4-methoxyphenyl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	5.0000	uM
cyclopentyl 4-(4-fluorophenyl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	8.0000	uM
cyclopentyl 6-methyl-4-(4-methylsulfanylphenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	8.0000	uM
ethyl 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate	267743: Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	ic50	9.5000	uM

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	6
sodium arsenite	affects cotreatment, decreases expression, increases expression	4
bisphenol A	affects expression, increases expression	2
Acetaminophen	decreases expression, increases expression	2
Air Pollutants	affects expression, increases abundance, decreases expression	2
Estradiol	affects expression, increases expression	2
ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate	decreases expression	1
dicrotophos	increases expression	1
lead acetate	affects cotreatment, decreases expression	1
cobaltous chloride	decreases expression	1
linalool	increases expression, increases reaction	1
3,4,5,3’,4’-pentachlorobiphenyl	affects expression	1
zinc chromate	decreases expression, increases abundance	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,2’,3’,4,4’,5-hexachlorobiphenyl	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
perfluorooctane sulfonic acid	decreases expression	1
pentabromodiphenyl ether	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	decreases expression, increases response to substance	1
jinfukang	increases expression	1
(+)-JQ1 compound	increases expression	1
Arbutin	decreases expression	1
Cisplatin	decreases expression	1
Ivermectin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL870441	Binding	Inhibition of human FATP4-mediated 12-BODIPY-lauric acid uptake in HEK293 cells	Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4. — Bioorg Med Chem Lett

Cellosaurus cell lines

5 cell lines: 4 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3HC	Abcam HEK293T SLC27A4 KO	Transformed cell line	Female
CVCL_D4KS	HCT116-SLC27A4-KO-c1	Cancer cell line	Male
CVCL_D4KT	HCT116-SLC27A4-KO-c4	Cancer cell line	Male
CVCL_TM69	HAP1 SLC27A4 (-) 1	Cancer cell line	Male
CVCL_TM70	HAP1 SLC27A4 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

6 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00421174	PHASE3	COMPLETED	Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)
NCT01222000	PHASE3	UNKNOWN	Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous
NCT03041038	PHASE2	COMPLETED	The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
NCT03738800	PHASE2	TERMINATED	A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
NCT00001292	Not specified	COMPLETED	Study of Scaling Disorders and Other Inherited Skin Diseases
NCT05312073	Not specified	COMPLETED	Study of in Vivo and in Vitro Transcriptomic and Proteomic Signatures in Unhereditary Ichtyosis